Neus Martínez-Bosch, Noelia Vilariño, Francesc Alameda, Sergi Mojal, Montserrat Arumí-Uria, Cristina Carrato, Iban Aldecoa, Teresa Ribalta, Noemí Vidal, Beatriz Bellosillo, Silvia Menéndez, Sonia Del Barco, Oscar Gallego, Estela Pineda, Raquel López-Martos, Ainhoa Hernández, Carlos Mesia, Anna Esteve-Codina, Nuria de la Iglesia, Carme Balañá, María Martínez-García, Pilar Navarro
Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment targets as well as diagnostic, prognostic, and/or predictive biomarkers are needed to improve outcomes in this population. The β-galactoside binding protein Galectin-1 (Gal-1) is a protein with a wide range of pro-tumor functions such as proliferation, invasion, angiogenesis, and immune suppression...
March 8, 2023: Cells